Empagliflozin

恩格列净

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameEmpagliflozin
Drug Alias Nameempagliflozine艾帕列净依帕列净empagliflozinum艾格列净 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsAcutely decompensated congestive heart failureIschemic StrokeHealthy Aging +[55] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2014/05/22
Country/TerritoryCzechiaBelgiumBulgaria +[63] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Nacional De Cardiologia Ignacio ChavezUtah State UniversityC.H. Boehringer Sohn Ag & Co. Kg +[47] 
Inactive CompaniesUniversity Medical Center GroningenUniversity Of CopenhagenSanofi +[14] 
Active IndicationsAcutely decompensated congestive heart failureIschemic StrokeHealthy Aging +[48] 
Inactive IndicationsWeight LossHypoglycemiaInsulin Resistance +[7] 

Other Information

ATC CodeA10BK03
Related LinksWikipediaDrugBankKEGG